{"name":"Advaxis, Inc.","slug":"advaxis-inc","ticker":"","exchange":"","domain":"","description":"Advaxis Immunotherapies Inc. was an American company that focused on the discovery, development, and commercialization of immunotherapies based on agenetically engineered platform based on Listeria monocytogenes. The company merged with Ayala Pharmaceuticals, with the newly formed company beginning operations under the name Ayala Pharmaceuticals in January 2023.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ADXS31-142","genericName":"ADXS31-142","slug":"adxs31-142","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"ADXS31-164","genericName":"ADXS31-164","slug":"adxs31-164","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"Axalimogene filolisbac","genericName":"Axalimogene filolisbac","slug":"axalimogene-filolisbac","indication":"Cervical cancer","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ADXS-503","genericName":"ADXS-503","slug":"adxs-503","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ADXS31-142","genericName":"ADXS31-142","slug":"adxs31-142","phase":"phase_1","mechanism":"Listeria monocytogenes-based immunotherapy targeting MUC1","indications":["Non-small cell lung cancer","Ovarian cancer"],"catalyst":""},{"name":"ADXS-503","genericName":"ADXS-503","slug":"adxs-503","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ADXS31-164","genericName":"ADXS31-164","slug":"adxs31-164","phase":"phase_1","mechanism":"Listeria monocytogenes-based immunotherapy targeting MUC1","indications":["Non-small cell lung cancer","Ovarian cancer"],"catalyst":""},{"name":"Axalimogene filolisbac","genericName":"Axalimogene filolisbac","slug":"axalimogene-filolisbac","phase":"phase_2","mechanism":"Lysosomal targeting of tumor cells via Listeria monocytogenes","indications":["Cervical cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQSElWTVpWSFBqQXZaWXdiS0x3LW43eVVLWmJnRkxiR0wwMXdsQmlUMDJXdE9LV0VPMU5FYWJqdlcyemdrY1JCVmFNVUV3eU5XNVJ3TXRQdjVJNFdmeWR6eEhJMk5fZkd0NDhDaUktQWFZTldxNUdWTFpwaER0T3YyMl9JVkd0WnRpWHdPUUZUYU9mM3B2Ynpua1JWNk9lcllpUHF4WWMwNVlmNGktU2d6TUhmR1JHZnZka2Nj?oc=5","date":"2026-03-12","type":"pipeline","source":"AD HOC NEWS","summary":"Ayala Pharmaceuticals: A Strategic Pivot to Milestone-Driven Value - AD HOC NEWS","headline":"Ayala Pharmaceuticals: A Strategic Pivot to Milestone-Driven Value","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFAxa2RkbUpXbUZlOFk4NnhfYXpCTWhYcmJMa1Y5ZzYxdFZhYVRwcll0WDcyYXg0SXdiUl9UVVlaREd0NFV2TkFjMDk2aGExQzVIZ2c4?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"ADXS Stock Price, News & Analysis | Ayala Pharm - Stock Titan","headline":"ADXS Stock Price, News & Analysis | Ayala Pharm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOeUM0RVBXVWh1MnM2UEN6QjV6d0t6aDBXQ0xwLWlaZk9QQUVzMXZiME04V0JLUHgtb2hDOW9wWTB1UEhCQWI0NVgtUF8wSE1tdU5pc3pmOFNIR3h4aXY2YWZoMTRYQnp6cEFqM1NJTlVTYTNlR2N1Q24tbmlBR0xCOVMzNGxVVVRkck4xdVNtWUxqM3d6MDB0NWZwb083ajdlYWVpV3BFTk1mcGFrQWQ1eXZKV2I5c09ScklhRDNNQ2ludEExdlVMRlVucThrVUlnZUdHTkUxbngySUIyc3h3M3VPZm5tdnFLUlBlanBzRTJZTmdUWXNLdkhybHFKYVBFNTFCbTM5eWpYWVBWc3c?oc=5","date":"2025-04-09","type":"pipeline","source":"Business Wire","summary":"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals - Business Wire","headline":"OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceut","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxQVTJMcDl1aW9RSGRIUmtZQjE4dlpVMnl5SEw4UzRnbXlkamFVSFlTUUNGbmFYcHNJNS1YQ3ZnX1NCUTY3Z3F2d0haSXNqOUROUVd4czdOWkY2bXROVm1tQl9BVDNSSmQ1aWx3QmNYMzRlVlVCWkp6ZFByR2pFRGRRX1c2X0lBUUowV0xZUndld20xTjRGX09IaVZwSFctMHJMeDQ4dlgyYlVMdU1rakpLdENaeFFSVDBIZVFvNHdRa2Z0WEc5dzZJc2ZubERCU2JKUkVkSVlfVl9mMl9JUHVLZllDWHQ1SHJkLVRGVXVqSzBSVVBSNFJINGI0ektuTzdmcEJCaGh3MzA5ODNOWEdtTzFZWDJBb1lseDBKMngzNDBuSmYySmFqdXMwWjZzdnJfdzNZV1M3VW5GRDlVbTQyREFZdEh0cFUwelltaU5QTzdsZ0RxVDhJSTN1S0tURF9O?oc=5","date":"2025-01-29","type":"trial","source":"BioSpace","summary":"OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipe","headline":"OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmace","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPeFQxUTR6YVZzOU9iVkE2MDhwM1d0U25LMXkwVmNlNG5QMEtQTDJCMXc3b2Mxdm5LaFZ3MVZObTBRT0hfaDIwZmY3VHplY1hiRm1yUEFCMFlPTW5Mak91T2tCdG9fQkhkYllYdTN1cm9keHFSZVN3ODZlQkJCSzFweTJGV09ma0ZDb3o0NjVpcmhYVU95Q3pn?oc=5","date":"2023-10-19","type":"deal","source":"Yahoo Finance","summary":"Ayala Pharmaceuticals Announces Closing of Merger with Biosight - Yahoo Finance","headline":"Ayala Pharmaceuticals Announces Closing of Merger with Biosight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNRjR2cGN1TC1Jclc3c3B2dXhBS25pd0ZGdTB5QVhTNk5tbFZOeG9fWlZpMzdaZGdsci1fRHN4QmF5VXdHSHpkdHI4Q0tMemRmbnRUTW5laDlieXJ6TlhwN3F0bjJxUHUtU3d2dXRTdmdyZV9yQk5vMnh1cVRWS2twTQ?oc=5","date":"2023-01-20","type":"deal","source":"NJBIZ","summary":"Advaxis completes merger to become Ayala Pharmaceuticals - NJBIZ","headline":"Advaxis completes merger to become Ayala Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPTU1meHBtdjNTY2xZT3U0Y2tjVHZ6X0pnUXNmNzRzbk56elFrZFRXcTVwVTQ2YzF0ZkdpaktHcDUzWGkzdlg0QlhfWW1YaVk5RWt6NkpFenhwTWhBUEVMeXRkdFVsRG5sNnB2VlVzakxueXkwcC1fRkRLYUZiLWxkREJUSHJLbzFnWmJ6enpkTnVGd2E0U1E?oc=5","date":"2023-01-19","type":"deal","source":"Yahoo Finance","summary":"Advaxis and Ayala Pharmaceuticals Complete Merger - Yahoo Finance","headline":"Advaxis and Ayala Pharmaceuticals Complete Merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBLZERONmVqbk9qVGVfU0o4OE1weDN3bFpBcnIzSk9iRmZmMFdzYnBsMkRycTZxQnVfOEZQUWgyVWdOb3ZQWVhfSHJwTGdTaDNLdDdqbGRLb25WWTNtRUxENVlTYjA2RDc3T0t6bTdpZy1qNDJaWm9SN0FzZDU1dw?oc=5","date":"2022-10-20","type":"deal","source":"Pharmaceutical Technology","summary":"Advaxis enters merger deal with biotech firm Ayala - Pharmaceutical Technology","headline":"Advaxis enters merger deal with biotech firm Ayala","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1VM3hqSzcwdWtqa05TRF85UWxjMHNXQzVtcWVvWGRraTJEV1hXQ1hJM3pOanhhR0QwVVVFbzZIVkFCYmtIRmpnX2NPOWhwTlRPSWFpNUdqZ0Y1cTdNeFdxVGUxMTFCYi1iUUs2UW1nYkVhbmlMdFVEVXQyNEU?oc=5","date":"2022-09-25","type":"pipeline","source":"Allied Market Research","summary":"Bone Cancer Treatment Market Size, Share & Growth, 2031 - Allied Market Research","headline":"Bone Cancer Treatment Market Size, Share & Growth, 2031","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBhVHdPbHdoR1k0YnV3OFpENE5WVDh2REFPTU5hbHdCMGtpZFZJVXRpd3Q1TjdzTUZ5NF9PZkFtdFoycEw3d3JNVzZNUXpJMmVESDhva3RkaXVLVWdjVjVwUjd3dUVwQ1dlelZzTFR3?oc=5","date":"2018-06-25","type":"pipeline","source":"njbmagazine.com","summary":"The NJ Biotech Boom - njbmagazine.com","headline":"The NJ Biotech Boom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQMzZzWWhKRGZkenhUYkpEelFzZ1hlbWQ3QmNMajdYbjVULUJxM3B6MU5ZT2d2T3BWb2NqV1lURXNhZ3Q1ZHNlcDJzRk93cUdaWjV5cW0xb2dHZEltSnlWNlVLZWdrMEFLRnZnVmdOWldwZHpjQXg2LW5CVzY5VkNzMnkzUjRoMzVHd25z?oc=5","date":"2018-03-13","type":"pipeline","source":"BioPharma Dive","summary":"Advaxis drops after clinical hold due to patient death - BioPharma Dive","headline":"Advaxis drops after clinical hold due to patient death","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOU2lMU1ZPbExIazRnZXhnQzFOa1FjZlJ0MlE4dTF3Q3JPdjBZWjY0ZC1YUFU1SVpMTEprNnhReGQzZXN2YUlPVzNjUkF0OERmOTVudUNyS2V1eGhuNXJDbi1Hd1owUkMtaUoycTRyeE0yc2pZUUpNeDBYMjIxQVlpTjIxSEcxT2dKRS0xalNHLTRkbVZiM2ttVDQ5dUc3dUkzaTBxaERQOUJwc1BJMEg4ckZaSGxOd3lfaFZMLWgzRDZaek93cWZOaDZwa0U1aFhmc3M2dWlYN2N3VndkLXE5MC1yQjE?oc=5","date":"2014-07-22","type":"trial","source":"AstraZeneca","summary":"MedImmune and Advaxis partner on immuno-oncology combination clinical trial - AstraZeneca","headline":"MedImmune and Advaxis partner on immuno-oncology combination clinical trial","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":3,"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}